SENAI Institute of Innovation (ISI) in Advanced Health Systems (CIMATEC ISI SAS), University Center SENAI/CIMATEC, National Service of Industrial Learning - SENAI, Salvador, Bahia, Brazil.
University Center SENAI/CIMATEC, National Service of Industrial Learning - SENAI, Salvador, Bahia, Brazil.
Recent Pat Nanotechnol. 2021;15(4):367-376. doi: 10.2174/1872210514666201223093321.
Cancer is caused by mutations in oncogenes and loss of tumor suppressor activity. Despite the efforts of the pharmaceutical industry to fight cancer, it is necessary to investigate new methods to enhance the action against this disease. In this scenario, liposome technology has emerged as a drug delivery system for cancer treatment. The objective of this study was to evaluate the use of liposome technology in the treatment of cancer through analysis of patent documents.
We analyzed prospective documents in the Derwent Innovation Index database.
A total of 203 patent documents were related to the area of interest, published between 2000 and 2020, and the USA and Japan were shown as countries with the largest number of publications. Moreover, most of these publications came from companies, however, also with the representation of important universities, mainly the University of California. According to the International Patent Classification, the codes most applicable to the documents were in the areas of human necessities and chemistry.
The results of this study showed that the study and application of liposomes for the development of cancer treatment tended to grow, along with the number of related patents.
癌症是由癌基因的突变和肿瘤抑制活性的丧失引起的。尽管制药行业为抗击癌症做出了努力，但仍有必要研究新的方法来增强对抗这种疾病的作用。在这种情况下，脂质体技术已成为癌症治疗的药物递送系统。本研究的目的是通过分析专利文献来评估脂质体技术在癌症治疗中的应用。
我们分析了德温特创新索引数据库中的前瞻性文件。
共有 203 篇专利文献与研究领域相关，发表于 2000 年至 2020 年期间，美国和日本是发表文献数量最多的国家。此外，这些出版物大多来自公司，但也有重要大学的代表，主要是加利福尼亚大学。根据国际专利分类，最适用于这些文献的代码是人类需求和化学领域。
本研究结果表明，随着相关专利数量的增加，对脂质体用于癌症治疗的研究和应用呈增长趋势。
